Open to debate. The motion: prevention of prostate cancer with a 5alpha-reductase inhibitor is feasible

Eur Urol. 2006 Feb;49(2):396-400. doi: 10.1016/j.eururo.2005.12.059.

Authors

Claus G Roehrborn¹, Yair Lotan, Andrea Tubaro, Cosimo de Nunzio

Affiliation

¹ Department of Urology, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA. [email protected]

PMID: 16455190
DOI: 10.1016/j.eururo.2005.12.059

No abstract available

MeSH terms

3-Oxo-5-alpha-Steroid 4-Dehydrogenase / metabolism
5-alpha Reductase Inhibitors*
Anticarcinogenic Agents / therapeutic use*
Antineoplastic Agents / therapeutic use
Chemoprevention
Clinical Trials as Topic
Enzyme Inhibitors / therapeutic use*
Humans
Male
Primary Prevention*
Prostatic Hyperplasia / drug therapy
Prostatic Hyperplasia / prevention & control
Prostatic Neoplasms / drug therapy*
Prostatic Neoplasms / enzymology
Prostatic Neoplasms / epidemiology
Prostatic Neoplasms / prevention & control*
Tumor Burden / drug effects
United States / epidemiology

Substances

5-alpha Reductase Inhibitors
Anticarcinogenic Agents
Antineoplastic Agents
Enzyme Inhibitors
3-Oxo-5-alpha-Steroid 4-Dehydrogenase